CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Clinical trials for CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug trio aims to tame tough cancers
Disease control OngoingThis study is testing a combination of three immunotherapy drugs—tocilizumab, ipilimumab, and nivolumab—in people with advanced melanoma, non-small cell lung cancer, or bladder cancer. The main goals are to see if adding tocilizumab is safe and if it helps the other two drugs wor…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 04, 2026 05:21 UTC
-
Trial aims to stop cancer drugs early using smart scans
Disease control OngoingThis study is testing whether doctors can safely stop a standard immunotherapy treatment early for patients with advanced melanoma. It uses PET scans and biopsies taken after one year of treatment to decide who can stop their medication. The goal is to see if patients can avoid u…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Major trial tests new drug to stop deadly skin Cancer's return
Disease control OngoingThis large study is testing if a newer immunotherapy drug, pembrolizumab, is better at preventing melanoma from coming back after surgery than the current standard treatments. It involves over 1,300 patients with stage III or IV melanoma who have had their cancer surgically remov…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Scientists test Triple-Threat drug combo against aggressive skin cancer
Disease control OngoingThis study is testing whether adding a third drug, navitoclax, to two existing melanoma drugs (dabrafenib and trametinib) can help shrink tumors more effectively. It involves adults with advanced, BRAF-mutant melanoma or other solid tumors that have spread or cannot be removed by…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
Cancer trial aims to crack the code on treatment sequence for deadly skin cancer
Disease control OngoingThis study is for people with advanced melanoma that has a specific BRAF gene mutation and cannot be removed by surgery. It is testing which order of two powerful treatment combinations leads to longer survival. One group starts with immunotherapy (ipilimumab + nivolumab) and swi…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New strategy: shrink tumors before surgery to fight advanced melanoma
Disease control OngoingThis study is comparing two different timing strategies for an immunotherapy drug called pembrolizumab in patients with high-risk melanoma that can be surgically removed. It aims to see if giving the drug *before* surgery (to shrink the tumor) works better than the standard appro…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New drug cocktail aims to wipe out melanoma before surgery
Disease control OngoingThis study tests whether giving drug combinations before surgery can help people with high-risk stage III melanoma. The trial involves 59 participants receiving either targeted cancer drugs, immunotherapy drugs, or both for several weeks before their operation. Researchers want t…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Scientists test new drug duo to fight tough cancers
Disease control OngoingThis early-stage study is testing a new combination of two drugs, sonidegib and pembrolizumab, for people with advanced solid tumors that have spread. The main goals are to find the safest dose of the combination and see if it helps shrink or control the cancer. The study is enro…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
Balancing act: fighting cancer while protecting a transplanted kidney
Disease control OngoingThis early-phase study is testing a combination of immunotherapy drugs (nivolumab and ipilimumab) along with standard transplant medications (tacrolimus and prednisone) in kidney transplant patients with advanced skin cancers that have spread or cannot be removed by surgery. The …
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New combo therapy trial offers hope for HIV patients with advanced cancers
Disease control OngoingThis is a small, early-stage safety study testing a combination of two cancer drugs, nivolumab and cabozantinib, in people living with HIV who have advanced solid tumors. The main goal is to see if the two-drug combination is safe and tolerable for this specific patient group. Re…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Can your diet boost cancer treatment? new study investigates
Disease control OngoingThis study is testing whether eating a high-fiber diet can improve gut health and help the immune system fight cancer in patients with advanced melanoma who are receiving standard immunotherapy. Fifty participants will be randomly assigned to follow either a high-fiber diet or a …
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Boosting the immune system to fight skin cancer before surgery
Disease control OngoingThis study is testing if a new drug combination works better than a standard drug alone to shrink melanoma tumors before surgery. It involves 60 adults with stage III melanoma that can be surgically removed. The goal is to see if the combination helps the immune system attack the…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Facebook groups fight skin cancer in families
Prevention OngoingThis study is testing whether private Facebook groups can help young melanoma survivors and their close family members prevent future skin cancer. Researchers are comparing two types of groups: one focused on skin cancer education and one on general healthy living. The goal is to…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Prevention
Last updated Mar 30, 2026 14:34 UTC
-
Tracking the hidden toll: study maps immunotherapy side effects in cancer survivors
Knowledge-focused OngoingThis study observes melanoma survivors who have completed surgery and are receiving immunotherapy drugs to prevent cancer return. Researchers follow 126 patients for two years to track side effects, symptoms like fatigue and depression, and quality of life. The goal is to underst…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Mar 24, 2026 12:01 UTC